Genus (GNS) Aperçu de l'action
Genus plc produit et vend de la génétique animale aux agriculteurs d'Amérique du Nord, d'Amérique latine, du Royaume-Uni, du reste de l'Europe, du Moyen-Orient, de la Russie, de l'Afrique et de l'Asie. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 1/6 |
| Croissance future | 0/6 |
| Performances passées | 1/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
GNS Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Genus plc Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | UK£24.62 |
| Plus haut sur 52 semaines | UK£32.29 |
| Plus bas sur 52 semaines | UK£18.90 |
| Bêta | 0.90 |
| Variation sur 1 mois | 2.24% |
| Variation sur 3 mois | -22.33% |
| Variation sur 1 an | 19.51% |
| Variation sur 3 ans | -1.36% |
| Variation sur 5 ans | -51.82% |
| Évolution depuis l'introduction en bourse | 1,723.70% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.
Mise à jour du récit • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.Mise à jour du récit • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.
Mise à jour du récit • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.Mise à jour du récit • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.Recent updates
Mise à jour du récit • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.Mise à jour du récit • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.Mise à jour du récit • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.Mise à jour du récit • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.Mise à jour du récit • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.Mise à jour du récit • Mar 06
GNS: China JV And Gene Editing Progress Will Support Medium Term Upside
Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.Mise à jour du récit • Feb 20
GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside
Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.Mise à jour du récit • Feb 06
GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook
Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.Mise à jour du récit • Jan 23
GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential
Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.Mise à jour du récit • Jan 08
GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk
Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.Article d’analyse • Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£21.95 based on 2 Stage Free Cash Flow to Equity Current share price of...Mise à jour du récit • Dec 22
GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks
Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.Mise à jour du récit • Dec 08
GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks
Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.Mise à jour du récit • Nov 24
GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns
Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.Article d’analyse • Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Genus plc ( LON:GNS ) is definitely a stock worth...Article d’analyse • Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217
Genus plc's ( LON:GNS ) investors are due to receive a payment of £0.217 per share on 5th of December. Including this...Article d’analyse • Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit
Genus plc's ( LON:GNS ) solid earnings announcement recently didn't do much to the stock price. Our analysis suggests...Article d’analyse • Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of December. This means...Mise à jour du récit • Sep 10
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.Article d’analyse • Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
The board of Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of...Article d’analyse • Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Despite an already strong run, Genus plc ( LON:GNS ) shares have been powering on, with a gain of 25% in the last...Article d’analyse • Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights The projected fair value for Genus is UK£25.58 based on 2 Stage Free Cash Flow to Equity Genus' UK£24.10...Article d’analyse • May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Genus plc ( LON:GNS ) shareholders would be excited to see that the share price has had a great month, posting a 36...Article d’analyse • Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
Key Insights The projected fair value for Genus is UK£20.55 based on 2 Stage Free Cash Flow to Equity Genus is...
Nouveau récit • Feb 11
Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position
Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.Article d’analyse • Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Genus plc ( LON:GNS ) shareholders are no doubt pleased to see that the share price has bounced 25% in the last month...Article d’analyse • Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S
Genus plc's ( LON:GNS ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a strong buy right now compared...Article d’analyse • Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217
Genus plc ( LON:GNS ) will pay a dividend of £0.217 on the 6th of December. This payment means the dividend yield will...Article d’analyse • Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings
The market for Genus plc's ( LON:GNS ) shares didn't move much after it posted weak earnings recently. We did some...Article d’analyse • Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next
Genus plc ( LON:GNS ) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to UK£17.10...Article d’analyse • Jun 16
The Price Is Right For Genus plc (LON:GNS)
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right now...Article d’analyse • Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£18.59 based on 2 Stage Free Cash Flow to Equity Genus' UK£17.18 share...Article d’analyse • Mar 25
Is Genus (LON:GNS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For
Genus plc ( LON:GNS ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The drop...Article d’analyse • Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.103 per share on the 28th of March. The dividend...Article d’analyse • Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 44x might make it look like a strong sell right now...Article d’analyse • Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?
Key Insights The projected fair value for Genus is UK£15.63 based on 2 Stage Free Cash Flow to Equity Genus is...Rendement pour les actionnaires
| GNS | GB Biotechs | GB Marché | |
|---|---|---|---|
| 7D | 4.1% | 3.5% | 1.8% |
| 1Y | 19.5% | 24.7% | 19.0% |
Rendement vs Industrie: GNS a sous-performé le secteur UK Biotechs qui a rapporté 24.7 % au cours de l'année écoulée.
Rendement vs marché: GNS correspond au marché UK qui a rapporté 19 % au cours de l'année écoulée.
Volatilité des prix
| GNS volatility | |
|---|---|
| GNS Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 12.1% |
| 10% least volatile stocks in GB Market | 3.1% |
Cours de l'action stable: GNS n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché UK.
Volatilité au fil du temps: La volatilité hebdomadaire de GNS ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1994 | 3,190 | JK Kokke | www.genusplc.com |
Genus plc produit et vend de la génétique animale aux agriculteurs d'Amérique du Nord, d'Amérique latine, du Royaume-Uni, du reste de l'Europe, du Moyen-Orient, de la Russie, de l'Afrique et de l'Asie. La société opère à travers trois segments : Genus PIC, Genus ABS et Genus Research and Development. Elle propose de la semence et des embryons de taureaux laitiers et bovins sous les marques Genus et Bovec ; des porcs reproducteurs et de la semence, ainsi que des services techniques et des conseils sous la marque PIC.
Genus plc Résumé des fondamentaux
| GNS statistiques fondamentales | |
|---|---|
| Capitalisation boursière | UK£1.65b |
| Bénéfices(TTM) | UK£47.50m |
| Recettes(TTM) | UK£672.00m |
34.7x
Ratio P/E2.5x
Ratio P/SLe site GNS est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| GNS compte de résultat (TTM) | |
|---|---|
| Recettes | UK£672.00m |
| Coût des recettes | UK£402.40m |
| Marge brute | UK£269.60m |
| Autres dépenses | UK£222.10m |
| Les revenus | UK£47.50m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
Sep 10, 2026
| Résultat par action (EPS) | 0.71 |
| Marge brute | 40.12% |
| Marge bénéficiaire nette | 7.07% |
| Ratio dettes/capitaux propres | 46.4% |
Quelles ont été les performances à long terme de GNS?
Voir les performances historiques et les comparaisonsDividendes
1.3%
Rendement actuel des dividendes46%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 14:39 |
| Cours de l'action en fin de journée | 2026/05/26 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Genus plc est couverte par 18 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Robert Chantry | Berenberg |
| Matthew Lloyd | BNP Paribas |
| Alexander Jones | BofA Global Research |